Skip to content

C3 Improving the Management of Critical Abnormal Findings in a Health Examination Population: A PDCA-Based Quality Improvement Study

C3 Improving the Management of Critical Abnormal Findings in a Health Examination Population: A PDCA-Based Quality Improvement Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127218
Enrollment
Unknown
Registered
2026-06-26
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common diseases in medicine

Interventions

Observation group:None

Sponsors

The Affiliated Yongchuan Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A total of 27,895 individuals who participated in physical examinations at the Physical Examination Center of Yongchuan Hospital Affiliated to Chongqing Medical University from January 2024 to April 2025 were selected, among whom a total of 1,526 had significant abnormal results.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Blood Pressure Measurement;Hematological Panel (Complete Blood Count, Glucose, Lipid Profile, Liver Function Tests, Renal Function Tests, Syphilis Serology, Rheumatoid Factor, Cardiac Enzymes, Amylase);Urinalysis Panel (Urinalysis, Urinary Microalbumin/Creatinine Ratio);Ultrasound Examination (Thyroid, Breast, Hepatobiliary Pancreas, Uterine Adnexa);Pulmonary CT Imaging;Electrocardiogram;Cervical Cancer Screening Panel (HPV Testing, ThinPrep Cytology Test, Cervical Cytology);Post-Examination Follow-up Status (Medical Visit and Treatment Outcomes);

Countries

China

Contacts

Public ContactChen Yexing

The Affiliated Yongchuan Hospital of Chongqing Medical University

doctor1282835734@163.com+86 10 12345678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026